YU30504A - Postupak za dobijanje supstituisanih pirazola - Google Patents

Postupak za dobijanje supstituisanih pirazola

Info

Publication number
YU30504A
YU30504A YU30504A YUP30504A YU30504A YU 30504 A YU30504 A YU 30504A YU 30504 A YU30504 A YU 30504A YU P30504 A YUP30504 A YU P30504A YU 30504 A YU30504 A YU 30504A
Authority
YU
Yugoslavia
Prior art keywords
substituted pyrazoles
making substituted
pyrazoles
making
tautomers
Prior art date
Application number
YU30504A
Other languages
English (en)
Inventor
Kimberley Allen
Dennis Anderson
John Baldus
Jerry Clark
Dan Dukesherer
Albert Edney
Patrick Lau
Michael Mao
Lisa Mcdermott
Jodie Moe
Partha Mudipalli
Win Naing
Tobin Schilke
Shaun Selness
Christine Seymour
Shekhar Viswanath
John Walker
Gopichand Yalamanchili
Original Assignee
Pharmacia Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corporation filed Critical Pharmacia Corporation
Publication of YU30504A publication Critical patent/YU30504A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)

Abstract

Ovaj pronalazak je usmeren na postupak za dobijanje supstituisanih pirazola (I), tautomera tih supstituisanih pirazola i soli tih supstituisanih pirazola i tautomera, gde su R3A, R3B, R3C, Y1, Y2, Y3, Y4 i Y5 definisani u ovoj prijavi. Ovaj postupak se sastoji od: formiranja smeše postupkom uvođenja hidrazona (II) i opciono supstituisanog benzoilhalida (III) u reaktor, pa zagrevanja te smeše iznad 50В°C (II); (III).[This invention is directed to a process for making substituted pyrazoles, (I) tautomers of the substituted pyrazoles, and salts of the substituted pyrazoles and tautomers, wherein R3A, R3B, R3C, Y1, Y2, Y3, Y4, and Y5 are as defined in the specification. The process comprises: forming a mixture by a process comprising introducing a hydrazone (II) and an optionally-substituted benzoyl halide (III) into a reactor, and heating the mixture to a temparature of greater than 50 В°C (II); and (III).
YU30504A 2001-09-25 2002-09-25 Postupak za dobijanje supstituisanih pirazola YU30504A (sh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32498701P 2001-09-25 2001-09-25
US38126102P 2002-05-17 2002-05-17
US38369102P 2002-05-28 2002-05-28

Publications (1)

Publication Number Publication Date
YU30504A true YU30504A (sh) 2006-08-17

Family

ID=27406371

Family Applications (1)

Application Number Title Priority Date Filing Date
YU30504A YU30504A (sh) 2001-09-25 2002-09-25 Postupak za dobijanje supstituisanih pirazola

Country Status (14)

Country Link
US (1) US6897318B2 (sh)
EP (1) EP1429773A1 (sh)
JP (1) JP2005508911A (sh)
KR (1) KR100697482B1 (sh)
CN (1) CN1321644C (sh)
AU (1) AU2002330096B2 (sh)
BR (1) BR0212812A (sh)
CA (1) CA2461095A1 (sh)
HK (1) HK1069535A1 (sh)
IL (1) IL161009A0 (sh)
MX (1) MXPA04002855A (sh)
PL (1) PL369497A1 (sh)
WO (1) WO2003026663A1 (sh)
YU (1) YU30504A (sh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7057049B2 (en) 2001-09-25 2006-06-06 Pharmacia Corporation Process for making substituted pyrazoles
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
WO2005061485A1 (en) * 2003-12-18 2005-07-07 Pharmacia Corporation Process for making substituted pyrazoles
EP2528901B9 (en) * 2010-01-27 2017-01-25 Boehringer Ingelheim International GmbH Pyrazole compounds as crth2 antagonists
WO2014167010A1 (en) 2013-04-12 2014-10-16 Bayer Cropscience Ag Novel triazole derivatives
JP2016522800A (ja) 2013-04-12 2016-08-04 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 新規トリアゾリンチオン誘導体
MX2015014365A (es) 2013-04-12 2015-12-07 Bayer Cropscience Ag Derivados de triazol novedosos.
CA2981379A1 (en) 2015-04-02 2016-10-06 Bayer Cropscience Aktiengesellschaft Novel 5-substituted imidazole derivatives
JP2018511608A (ja) 2015-04-02 2018-04-26 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 殺真菌剤としてのトリアゾール誘導体
MX2019002820A (es) 2016-09-13 2019-08-01 Bayer Cropscience Ag Combinaciones de compuesto activo que comprenden un derivado de imidazol sustituido en la posicion 5.
US20200045972A1 (en) 2016-09-29 2020-02-13 Bayer Cropscience Aktiengesellschaft Novel 5-substituted imidazolylmethyl derivatives
BR112019006448A2 (pt) 2016-09-29 2019-06-25 Bayer Cropscience Ag novos derivados de 5-imidazol substituídos
CN109983000A (zh) 2016-09-29 2019-07-05 拜耳作物科学股份公司 新的5-取代的咪唑基甲基衍生物
BR112020009446A2 (pt) 2017-11-13 2020-11-03 Bayer Aktiengesellschaft derivados de tetrazólio propila e seu uso como fungicida

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1261124B (de) 1961-09-22 1968-02-15 Hoechst Ag Verfahren zur Herstellung von Pyrazolen
GB1245283A (en) 1968-10-04 1971-09-08 Labaz Pyrazole derivatives
US3984431A (en) 1972-03-15 1976-10-05 Claude Gueremy Derivatives of pyrazole-5-acetic acid
FR2509729A1 (fr) 1981-07-15 1983-01-21 Pharmindustrie Nouveau procede de preparation de derives du diphenyl-3,4 methyl-5 pyrazole
DE3300795A1 (de) 1983-01-12 1984-07-12 Bayer Ag, 5090 Leverkusen Substituierte 4-imidazolyl-pyrazole, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
JP2753659B2 (ja) 1990-09-03 1998-05-20 株式会社大塚製薬工場 ピラゾール誘導体
JPH04145081A (ja) 1990-10-06 1992-05-19 Kumiai Chem Ind Co Ltd ピラゾールカルボン酸誘導体及び除草剤
AU1988692A (en) * 1991-04-24 1992-12-21 E.I. Du Pont De Nemours And Company Fungicidal pyrazoles, pyrazolines and tetrahydropyridazines
GB9204958D0 (en) 1992-03-06 1992-04-22 Fujisawa Pharmaceutical Co Thiazole derivatives
DE4328228A1 (de) 1993-08-23 1995-03-02 Basf Ag Verfahren zur Herstellung von Pyrazol und dessen Derivaten
US5559137A (en) 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5486534A (en) 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
JPH0899975A (ja) 1994-08-05 1996-04-16 Nippon Bayeragrochem Kk ５員複素環置換テトラゾリノン誘導体および除草剤
JPH11508267A (ja) 1995-06-26 1999-07-21 藤沢薬品工業株式会社 ピラゾール化合物および医薬組成物
US6077850A (en) 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EP0983260A2 (en) 1997-05-22 2000-03-08 G.D. Searle & Co. 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
HUP0001880A3 (en) 1997-05-22 2002-03-28 G D Searle & Co Chicago Substituted pyrazoles as p38 kinase inhibitors
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
EP1077971A1 (en) 1998-05-14 2001-02-28 G.D. SEARLE & CO. 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
WO2000031072A1 (en) 1998-11-20 2000-06-02 G.D. Searle & Co. Process for making 5-substituted pyrazoles using dithietanes

Also Published As

Publication number Publication date
CN1575176A (zh) 2005-02-02
EP1429773A1 (en) 2004-06-23
KR100697482B1 (ko) 2007-03-20
MXPA04002855A (es) 2004-07-05
US20030144302A1 (en) 2003-07-31
US6897318B2 (en) 2005-05-24
CA2461095A1 (en) 2003-04-03
WO2003026663A1 (en) 2003-04-03
AU2002330096B2 (en) 2007-11-08
PL369497A1 (en) 2005-04-18
IL161009A0 (en) 2004-08-31
KR20040081417A (ko) 2004-09-21
JP2005508911A (ja) 2005-04-07
CN1321644C (zh) 2007-06-20
HK1069535A1 (en) 2005-05-27
BR0212812A (pt) 2004-08-03

Similar Documents

Publication Publication Date Title
YU30504A (sh) Postupak za dobijanje supstituisanih pirazola
GEP20074135B (en) Process for the synthesis of (is)-4,5-dimethoxy-1-(methylaminomethyl)- benzocyclobutane and addition salts thereof, and to the application thereof in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
EP1180371A4 (en) AGENTS PROMOTING THE FORMATION OF A BASIC SKIN MEMBRANE, AGENTS PROMOTING THE FORMATION OF ARTIFICIAL SKIN AND METHOD FOR PRODUCING ARTIFICIAL SKIN
MY127149A (en) 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
MXPA02012795A (es) Carvedilol.
ZA200410000B (en) Method for producing C13-alcohol mixtures
HK1070063A1 (en) Stable polymorph of flibanserin, technical processfor its preparation and the use thereof for prepa ring medicaments
HK1089444A1 (en) Dihydropteridinones, method for the production and use thereof in the form of drugs
WO2002071827A3 (en) Retinoid x receptor modulators
JP2004513603A5 (sh)
UA96957C2 (ru) Способ получения галогенидов n-алкилнальтрексона
TW200607763A (en) Method of preparing nano scale nickel powders by wet reducing process
AR039857A1 (es) Preparaciones de una sulfinilacetamida
ZA200308353B (en) Compaction process for manufacture of sodium phenytoin dosage form.
IL198801A0 (en) Process for preparing 3,5-di-omicron-acyl-2-fluoro-2-c-methyl-d-ribono-gamma-lactone
HUP0101166A3 (en) Novel nucleotid sequenzen encoding the dapc gene and process for the production of l-lysine
GB2377225B (en) Process for the production of low ash fuel
HK1049828A1 (en) Continuous adiabatic process for preparing nitrochlorobenzene
GB9929485D0 (en) Tramadol salts thereof and process for their preparation
TW200508174A (en) Process for producing cumene
IL175834A (en) Process and intermediates for producing (3-oxo-2,3-dihydro-1h-isoindol-1-yl) acetylguanidine derivatives, some novel salts thereof and their use for production of medicaments
WO2001049651A3 (de) Aminomethyl-phenyl-cyclohexanonderivate
DK1399138T3 (da) Fremgangsmåde til fremstilling af faste formuleringer af natrium-3-hydroxy-3-methylbutyrat
MXPA02006674A (es) Proceso novedoso para la preparacion de alfa-(2,4-disulfofenil)-n-ter-butilnitrona y las sales farmaceuticamente aceptables de la misma.
AU2002219127A1 (en) Process for the production of ceftifur sodium salt